Revvity said it plans to divest its China immunodiagnostics business after entering a letter of intent with an undisclosed buyer, with a definitive agreement expected in Q2 2026. Revvity expects completion in 2027 subject to regulatory approvals. The immunodiagnostics segment accounted for about 6% of Revvity’s fiscal 2025 revenue, and the planned divestiture is projected to reduce Revvity’s expected 2026 revenue guidance by about 4.5% versus its prior outlook. The company also revised pro forma revenue and EPS guidance and expects an improved organic growth rate after the asset exit. Revvity’s change is positioned by CFO Max Krakowiak as a “bold decision” aimed at streamlining operations and reducing uncertainty from a challenging China market. For clinical and laboratory services players, cross-border diagnostics divestitures can reshape competitive positioning in immunoassays and shift capital toward areas aligned with operational strengths and margin targets.